Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis | Zendy

Edward J. Mills | Zendy; Mills | Zendy

Open Access

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis

Author(s) -

Edward J. Mills,

Mills

Publication year - 2012

Publication title -

clinical and experimental gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.113

H-Index - 30

ISSN - 1178-7023

DOI - 10.2147/ceg.s28253

Subject(s) - ribavirin , medicine , discontinuation , gastroenterology , alpha interferon , hepatitis c , alpha (finance) , randomized controlled trial , relative risk , meta analysis , combination therapy , clinical trial , peginterferon alfa 2a , confidence interval , chronic hepatitis , surgery , virology , interferon , virus , construct validity , patient satisfaction

With the development of new direct acting antiviral (DAA) therapy for hepatitis C, the backbone peginterferon alpha used may be of importance in maximizing treatment outcomes. To this end, the rates of sustained virologic response (SVR), relapse, and treatment discontinuation among hepatitis C genotype 1-infected patients given peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin were determined using a meta-analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research